Effets du traitement de substitution androgénique sur le profil lipidique de l'homme hypogonadique.

Androgens; Aged; Aging; Androgens/adverse effects; Androgens/therapeutic use; Humans; Hyperlipidemias/chemically induced; Hypogonadism/drug therapy; Male; Middle Aged; Lipid Metabolism; Aging male; Androgens substitutive therapy; Andropause; Hypogonadal men; Lipids; Medicine (all)

Abstract :

[en] The decrease in serum bioavailable testosterone level may be responsible for the catabolic sequelae noticed in the ageing male (decrease in libido, decrease in muscle mass, osteoporosis and increase in adiposity). After brief review of androgens and lipids metabolism as well as their modifications with ageing, we propose to present the current knowledge of the effects of androgen substitution on lipid profile in hypogonadal men.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Schleich, FLorence ; Université de Liège - ULiège > Département des sciences précliniques MI > Anatomie et cytologie pathologiques

Language :

French

Title :

Effets du traitement de substitution androgénique sur le profil lipidique de l'homme hypogonadique.

Alternative titles :

[en] Effects of androgen substitution on lipid profiles in hypogonadal men.

Publication date :

November 2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Be

Volume :

Issue :

Pages :

681 - 689

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 18 February 2024

Statistics

Number of views

4 (0 by ULiège)

Number of downloads

2 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Legros J-J.- Vers un consensus pour le traitement androgénique substitutif de l'andropause? Rev Med Liege, 2000, 55, 449-453.
Mauras N, Hayes V, Welch S, et al.- Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab, 1998, 83, 1886-1892.
Snyder PJ, Peachey H, Hannoush P, et al.- Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab, 1999, 84, 2467-2653.
Ly L, Jimenez M, Zhuang T, et al.- A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab, 2001, 86, 4078-4088.
Snyder PJ, Peachey H, Hannoush P, et al.- Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab, 1999, 84, 1966-1972.
Site andropause.prov-liege.be/effets/index.jsp
Jeffcoate SL, Brocks RV, Lin NY, et al.- Androgen production in hypogonadal men. J Endocrinol, 1967, 37, 401-411.
Mathieu A, Bruwier M, Allouch A, et al.- Indications et contre-indications du traitement par androgènes chez l'homme de plus de 50 ans. Med Hyg, 2001, 59, 1610-1614.
Basaria S, Dobs AS.- Hypogonadism and androgen replacement therapy in elderly men. Am J Med, 2001, 110, 563-572.
Wheeler MJ.- Determination of bio-available testosterone. Ann Clin Biochem, 1995, 32, 345-357.
Lejeune H, Déchaud H, Pugeat M.- Intérêt du dosage de testostérone biodisponible pour le diagnostic du déficit androgénique chez l'homme âgé. Am Endoc, 2003, sous presse.
Hennen G.- Endocrinologie. De Boeck Université, Bruxelles, 2001, 75-103.
Gray A, Feldman HA, McKinley JB, et al.- Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab, 1991, 73, 1016-1025.
Purifoy FE, Koopmans LH, Mayes DM.- Age differences in serum androgen levels in normal adult males. Hum Biol, 1981, 53, 499-511.
Desylpere JP, Vermeulen A.- Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab, 1984, 59, 955-962.
Vermeulen A, Kaufman JM, Giagulli VA.- Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab, 1996, 81, 1821-1826.
Feldman HA, McKinlay JB, Longcope C.- Hypogonadism: correlates in a large random sample of Massachusetts men. Proceedings of the 79th Annual Meeting of The Endocrine Society, 1997, 1-317.
Neaves WB, Johnson L, Porter JC, et al.- Leydig cell numbers, daily sperm production and serum gonadotrophin levels in aging men. J Clin Endocrinol Metab, 1984, 59, 756-763.
Vermeulen A, Desylpere JP.- Intratesticular unconjugated steroids in elderly men. J Steroid Biochem, 1986, 24, 1079-1089.
Suoranta H.- Changes in small blood vessels of the adult human testes in relation to age and some pathological conditions. Virchows Arch (Pathol Anat), 1971, 352, 765-781.
Desylpere JP, Vermeulen A.- Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. J Clin Endocrinol Metab, 1989, 68, 68-72.
Vermeulen A, Desylpere JP, Kaufman JM.- Influence of antiopioids and luteinizing hormone pulsatility in aging men. J Clin Endocrinol Metab, 1989, 68, 68-72.
Winters SJ, Sherins RJ, Troen P- The gonadotropin suppressive activity of androgens is increased in elderly men. Metabolism, 1984, 33, 1052-1059.
Hajjar RR, Kaiser FE, Morley JE.- Outcomes of long-term testosterone replacement in older hypogonadal males. A retrospective analysis. J Clin Endocrinol Metab, 1997, 82, 3793-3796.
Meikle AW, Stanish WM, Taylor N, et al.- Familial effects on plasma sex-steroid content in man: testosterone, estradiol and sex hormone-binding-globulin. Metabolism, 1982, 31, 6-9.
Bhasin S, Bagatell CJ, Bremner WJ, et al.- Issues in testosterone replacement in older men. J Clin Endocrinol Metab, 1998, 83, 3435-3448.
Bagatell CJ, Bremmer WJ.- Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis, 1995, 38, 255-271.
Meriggiola MC, Marcovina S, Paulsen CA, et al.- Testosterone enanthate at a dose of 200mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl, 1995, 18, 237-242.
Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al.- Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis, 1996, 21, 35-43.
Kantor MA, Bianchi A, Bernier D, et al.- Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exerc, 1985, 17, 462-465.
Sorva R, Kuusi T, Taskinen MR, et al.- Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis, 69, 191-197.
Heiss G, Johnson NJ, Reiland S, et al.- The epidemiology of plasma high density lipoproteins cholesterol levels. Circulation, 1980, 62 (suppl), 116-136.
Xu X, De Pergola G, Bjorntorp P.- The effects of androgens on the regulation of lipolysis in adipose percursor cells. Endocrinology, 1990, 126, 1229-1234.
Friedle KE, Hannan C, Jones RE, et al.- High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism, 1990, 39, 69-74.
Jockenhovel F, Bullmann C, Schubert M, et al.- Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism, 1999, 48, 590-596.
Bagatell CJ, Bremmer WJ.- Androgens in men: uses and abuses. N Engl J Med, 1996, 334, 707-714.
Uyanik BS, Ari Z, Gumus B, et al.- Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J, 1997, 38, 73-82.
Nestler J, Barlascini CO, Clore JN, et al.- Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab, 1988, 66, 57-61.
Arver S, Dobs AS, Meikle AW, et al.- Long-term efficacity and safety of a permeation-enhaned testosterone transdermal system in hypogonadal men. Clin Endocrinol, 1997, 47, 727-737.
Kenny AM, Prestwood KM, Gruman CA, et al.- Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci, 2002, 57, 460-465.
Wang C, Swerdloff R, Iranmanesh A, et al.- Transdermal testosterone gel improves sexual function, mood, muscle strenght, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab, 2000, 85, 2839-2853.
Sulcova J, Hill M, Masek Z, et al.- Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men. Physiol Res, 2001, 50, 9-18.
Sulcova J, Hill M, Hampl R, et al.- Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in men. Physiol Res, 2000, 49, 685-693.
Snyder PJ, Peachey H, Berlin JA, et al.- Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med, 111, 255-260.
Dobs AS, Meikle AW, Aver S, et al.- Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab, 1999, 84, 3469-3478.
Kenny AM, Prestwood KM, Raisz LG.- Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res, 2000, 26, 153-168.
Morley JE, Perry HM, Kaiser FE, et al.- Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Doc, 1993, 41, 149-152.
Ellvin FM, Plunkett-Reid K, Rumilla AE.- The long-term beneficial effect of low-dose testosterone in the aging male. Proceedings of the 79th Annual Meeting of the Endocrine Society, Minneapolis, 1997, Abst P236.
Sih R, Morley JE, Kaiser FE, et al.- Testosterone replacement in older hypogonadal men - a 12 month randomized controlled trial. J Clin Endocrinol Metab, 1997, 82, 1661-1667.
Barret-Connor E.- Testosterone, HDL cholesterol, and cardiovascular disease in men, in Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C, eds. Pharmacology, biology, and clinical applications of androgens. Wiley & Sons, New-York, 1996, 215-223.
Tan KCB, Shiu SWN, Pang RWC, et al.- Effects of testosterone replacement on HDL subfractions and apolipoprotein A-1 containing lipoproteins. Clin Endocrinol, 1998, 48, 187-194.
Tenover JS.- Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab, 1992, 75, 1092-1098.
Whistel EA, Boyko EJ, Matsumoto AM, et al.- Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med, 2001, 111, 261-269.
Berg G, Schreier L, Geloso G, et al.- Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men. Horm Metab Res, 2002, 34, 87-92.
Rabijewski M, Adamkiewicz M, Zgliczynski S.- The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men. Pol Arch Med Wewn, 1998, 100, 212-221.
Ozata M, Yildirimkaya M, Bulur M, et al.- Effects of gonadotropin and testosterone treatments on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab, 1996, 81, 3372-3378.
Dobs AS, Bachorik PS, Arver S, et al.- Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab, 2001, 86, 1026-1033.
Hauner H, Stangl K, Burger K, et al.- Sex hormone concentrations in men with angiographically assessed coronary artery disease-relationship to obesity and body fat distribution. Klin Wochenschr, 1991, 69, 664-668.
Nieschlag E, Behre HM, eds.- Testosterone: action, deficiency, substitution. 2nd ed. Ed Heidelberg/New York, 1998.
Snyder PJ, Lawrence DA.- Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab, 1980, 51, 1335-1339.
von Eckardstein S, Nieschlag E.- Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl, 2002, 23, 419-425.
Nieschlag E, Behre HM.- Pharmacology and clinical uses of testosterone, in Nieschlag E, Behre HM, et al. Testosterone: action, deficiency, substitution. 2nd ed. Springer-Verlag, Berlin, 1998, 293-328.
Elbers JMH, Grootenhuis AJ.- New tissue-selective androgens: perspectives in the treatment of androgen deficits. Am Endoc, 2003, sous presse.
Kumar N, Didolkar AK, Monder C, et al.- The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology, 1992, 130, 3677-3683.
Anderson RA, Martin CW, Kung AW, et al.- 7α -methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab, 1999, 84, 3556-3562.
Anderson RA, Malone NJ, Sundaram K.- Differential effects of 7α-methyl-19-nortestosterone (MENT) on prostate volume, bone mineral density and muscle mass in hypogonadal men. ENDO 2002 - 84th Annu Meet Endocrine Soc (June 19-22, San Fransisco) 2002, Abst P2-649.
Hamann LG, Mani NS, Davis RL, et al.- Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g-]-quinoline (LG121071). J Med Chem, 1999, 42, 210-212.
Rosen J, Negro-Vilar A.- New, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle improved safety profile. J Musculoskel Neuron Interact, 2002, 2, 222-224.
Gao W, Chung K, Kearbey JD, et al.- Pharmacologic effects of Androxolutamide (GTx-007) on male rats of varying hormonal status. ENDO 2002 - 84th Annu Meet Endocrine Soc (June 19-22, San Fransisco) 2002, Abst P2-487.